Additive protection of the ischemic heart ex vivo by combined treatment with δ-protein kinase C inhibitor and ε-protein kinase C activator

Circulation

Volumn 108, Issue 7, 2003, Pages 869-875

  Inagaki, Koichi ^a   Hahn, Harvey S ^b   Dorn II, Gerald W ^b   Mochly Rosen, Daria ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Cardioprotection; Enzymes; Ischemia; Kinases; Reperfusion

Indexed keywords

CREATINE KINASE; PROTEIN KINASE C ACTIVATOR; PROTEIN KINASE C DELTA INHIBITOR; PROTEIN KINASE C EPSILON; PROTEIN KINASE C INHIBITOR; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HEART FUNCTION; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISOLATED HEART; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; CARDIOTONIC AGENTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME ACTIVATORS; ENZYME INHIBITORS; HEART; ISCHEMIC PRECONDITIONING, MYOCARDIAL; ISOENZYMES; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MYOCARDIAL ISCHEMIA; OLIGOPEPTIDES; PEPTIDES; PERFUSION; PROTEIN KINASE C; PROTEIN KINASE C-DELTA; PROTEIN KINASE C-EPSILON; RATS; RATS, WISTAR; REPERFUSION INJURY;

EID: 0041932511     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000081943.93653.73     Document Type: Article

References (35)

1. Nishizuka Y. Studies and perspectives of protein kinase C. Science. 1986;233:305-312.
2. Nakano A, Cohen MV, Downey JM. Ischemic preconditioning: from basic mechanisms to clinical applications. Pharmacol Ther. 2000;86:263-275.
3. Gray MO, Karliner JS, Mochly-Rosen D. A selective epsilon-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death. J Biol Chem. 1997;272:30945-30951.
4. Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol. 1994;266: H1145-H1152.
5. Disatnik MH, Buraggi G, Mochly-Rosen D. Localization of protein kinase C isozymes in cardiac myocytes. Exp Cell Res. 1994;210:287-297.
6. Steinberg SF, Goldberg M, Rybin VO. Protein kinase C isoform diversity in the heart. J Mol Cell Cardiol. 1995;27:141-153.
7. Souroujon MC, Mochly-Rosen D. Peptide modulators of protein-protein interactions in intracellular signaling. Nat Biotechnol. 1998;16:919-924.
8. Mochly-Rosen D, Henrich CJ, Cheever L, et al. A protein kinase C isozyme is translocated to cytoskeletal elements on activation. Cell Regul. 1990;1:693-706.
9. Mochly-Rosen D. Localization of protein kinases by anchoring proteins: a theme in signal transduction. Science. 1995;268:247-251.
10. Chen L, Hahn H, Wu G, et al. Opposing cardioprotecfive actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci U S A. 2001;98:11114-11119.
11. Dorn GW II, Souroujon MC, Liron T, et al. Sustained in vivo cardiac protection by a rationally designed peptide that causes epsilon protein kinase C translocation. Proc Natl Acad Sci U S A. 1999;96:12798-12803.
12. Chen C, Mochly-Rosen D. Opposing effects of delta and epsilon PKC in ethanol-induced cardioprotection. J Mol Cell Cardiol. 2001;33:581-585.
13. Schwarze SR, Ho A, Vocero-Akbani A, et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999;285:1569-1572.
14. Chen L, Wright LR, Chen CH, et al. Molecular transporters for peptides: delivery of a cardioprotective epsilonPKC agonist peptide into cells and intact ischemic heart using a transport system, R(7). Chem Biol. 2001;8:1123-1129.
15. Sato M, Engelman RM, Otani H, et al. Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: implication of bradykinin-dependent and bradykinin-independent mechanisms. Circulation. 2000;102(suppl III):III-346-III-351.
16. Hahn HS, Yussman MG, Toyokawa T, et al. Ischemic protection and myofibrillar cardiomyopathy: dose-dependent effects of in vivo deltaPKC inhibition. Circ Res. 2002;91:741-748.
17. Mochly-Rosen D, Wu G, Hahn H, et al. Cardiotrophic effects of protein kinase C epsilon: analysis by in vivo modulation of PKCepsilon translocation. Circ Res. 2000;86:1173-1179.
18. Bolli R. Oxygen-derived free radicals and myocardial reperfusion injury: an overview. Cardiovasc Drugs Ther. 1991;5(suppl 2):249-268.
19. Saraste A, Pulkki K, Kallajoki M, et al. Apoptosis in human acute myocardial infarction. Circulation. 1997;95:320-323.
20. Gottlieb RA, Burleson KO, Kloner RA, et al. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest. 1994;94:1621-1628.
21. Fliss H, Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res. 1996;79:949-956.
22. Mischak H, Goodnight JA, Kolch W, et al. Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J Biol Chem. 1993;268:6090-6096.
23. Scarabelli T, Stephanou A, Rayment N, et al. Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury. Circulation. 2001;104:253-256.
24. Stewart DJ, Kubac G, Costello KB, et al. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol. 1991;18:38-43.
25. Ezra D, Goldstein RE, Czaja JF, et al. Lethal ischemia due to intracoronary endothelin in pigs. Am J Physiol. 1989;257:H339-H343.
26. Galiuto L, DeMaria AN, del Balzo U, et al. Ischemia-reperfusion injury at the microvascular level: treatment by endothelin A-selective antagonist and evaluation by myocardial contrast echocardiography. Circulation. 2000;102:3111-3116.
27. Clerk A, Bogoyevitch MA, Anderson MB, et al. Differential activation of protein kinase C isoforms by endothelin-1 and phenylephrine and subsequent stimulation of p42 and p44 mitogen- activated protein kinases in ventricular myocytes cultured from neonatal rat hearts. J Biol Chem. 1994;269:32848-32857.
28. Ping P, Zhang J, Qiu Y, et al. Ischemic preconditioning induces selective translocation of protein kinase C isoforms epsilon and eta in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ Res. 1997;81:404-414.
29. Mitchell MB, Meng X, Ao L, et al. Preconditioning of isolated rat heart is mediated by protein kinase C. Circ Res. 1995;76:73-81.
30. Liu GS, Cohen MV, Mochly-Rosen D, et al. Protein kinase C-epsilon is responsible for the protection of preconditioning in rabbit cardiomyocytes. J Mol Cell Cardiol. 1999;31:1937-1948.
31. + production. J Mol Cell Cardiol. 2002;34:361-367.
32. Saurin AT, Pennington DJ, Raat NJ, et al. Targeted disruption of the protein kinase C epsilon gene abolishes the infarct size reduction that follows ischaemic preconditioning of isolated buffer-perfused mouse hearts. Cardiovasc Res. 2002;55:672-680.
33. Kawamura S, Yoshida K, Miura T, et al. Ischemic preconditioning translocates PKC-delta and -epsilon, which mediate functional protection in isolated rat heart. Am J Physiol. 1998;275:H2266-H2271.
34. Zhao J, Renner O, Wightman L, et al. The expression of constitutively active isotypes of protein kinase C to investigate preconditioning. J Biol Chem 1998;273:23072-23079.
35. Zhao J, Heads RJ, Wightman L, et al. PKC-mediated cardioprotection requires adenosine receptor reoccupation. Circulation. 1998;98(suppl I):I-71.